DOCSLIB.ORG

DE H 2281 001 PAR.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DE H 2281 001 PAR.Pdf Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure RMS Public Assessment Report Latanoprost Malcosa 0,005% Xalaprost 0,005% Laxatan 0,005% Pharmecol 0.005% DE/H/1999/001/DC DE/H/2281/001/DC DE/H/2282/001/DC DE/H/2382/001/DC Applicant: Malcosa Ltd. Reference Member State DE Date of this report: 06.12.2010 The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health. 1/30 CONTENTS ADMINISTRATIVE INFORMATION .............................................................................................. 3 I. RECOMMENDATION ................................................................................................................ 4 II. EXECUTIVE SUMMARY....................................................................................................... 4 II.1 Problem statement..................................................................................................................... 4 II.2 About the product ..................................................................................................................... 4 II.3 General comments on the submitted dossier .......................................................................... 5 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles..6 III. SCIENTIFIC OVERVIEW AND DISCUSSION ................................................................... 6 III.1 Quality aspects....................................................................................................................... 6 III.2 Nonclinical aspects ................................................................................................................ 7 III.3 Clinical aspects ...................................................................................................................... 7 IV. BENEFIT RISK ASSESSMENT ........................................................................................... 30 V. Package Leaflet (PL)/Assessment of User Testing ............................................................... 30 2/30 ADMINISTRATIVE INFORMATION a) Latanoprost Malcosa 0,005% Proposed name of the medicinal b) Xalaprost 0,005% product in the RMS c) Laxatan 0,005% d) Pharmecol 0.005% INN (or common name) of the active Latanoprost substance(s): Pharmaco-therapeutic group S01EE01 (ATC Code): Pharmaceutical form(s) and Eye drops, solution, 50 microgram/ml strength(s): a) DE/H/1999/001/DC Reference Number for the b) DE/H/2281/001/DC Decentralised Procedure c) DE/H/2282/001/DC d) DE/H/2382/001/DC Reference Member State: DE a) BG, CY, EL, ES, IT, PL, PT, RO b) BG, CZ, HU, PL, RO, SK Member States concerned: c) AT, UK d) BG Malcosa Ltd. Acropolis Tower, 66 Acropolis avenue Applicant (name and address) 2012 Strovolos - Nicosia Cyprus Malcosa Ltd. Names and addresses of Acropolis Tower, 66 Acropolis avenue manufacturers responsible for batch release in the EEA 2012 Strovolos - Nicosia Cyprus 3/30 A) RECOMMENDATION Based on the review of the data and the Applicant’s response to the questions raised by RMS and CMS on quality, safety and efficacy, the RMS considers that the application for Latanoprost Malcosa 0,005%, in the treatment of Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension, is approvable as satisfactory responses are given and the applicant committed to perform a number of post authorisation follow- up measures. EXECUTIVE SUMMARY a.1 Problem statement The submitted documentation is in accordance with a "generic application". The application refers to an essential similar original product granted for more than 10 years in the Community according to Directive 2001/83/EC Article 10(1). This mutual recognition application concerns a generic version of Latanoprost. Latanoprost Eye drops solution of 0.005% is registered in most of the European countries under the brand name of Xalatan® by Pfizer. The data protection period is already expired and reference has been made to the non-clinical and clinical documentation of the reference product. The Marketing Authorization for Xalatan 0.005% eye drops solution was first granted for the UK market on December 16, 1996. ® The product Latanoprost was developed as a generic alternative to Xalatan ophthalmic solution (Latanoprost 50μg/ml, Pfizer) with minor changes in the composition (see confidential ANNEX). The product is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolarity of approximately 270mOsmol/kg. Each millilitre of Latanoprost finished product contains 50 micrograms of Latanoprost. Benzalkonium chloride, 0.02 % is added as a preservative. The inactive ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous and water for injection. The present Product License application is therefore submitted under Directive 2001/83/EC, Article 10.1 (a) (iii) in cross-reference to the pharmaco-toxicological and clinical data supporting the brand leader Xalatan® ophthalmic solution 50 μg/ml a.2 About the product The active substance latanoprost, a prostaglandin F2analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure by increasing the outflow of aqueous humour. Reduction of the intraocular pressure in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. Pressure reduction is maintained for at least 24 hours. 4/30 Latanoprost Malcosa is indicated in the treatment of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension. The recommended therapy is one eye drop in the affected eye(s) once daily. Optimal effect is obtained if Xalatan is administered in the evening. A possible risk management strategy is not yet established, but will be developed by the company. a.3 General comments on the submitted dossier Legal basis: The application of Latanoprost Malcosa is submitted under Directive 2001/83/EC, Article 10.1 (a) (iii) in cross-reference to the pharmaco-toxicological and clinical data supporting the originator Xalatan® ophthalmic solution 50 μg/ml. The type of marketing authorisation application incl. reference to legal basis of the application is appropriate. The Reference medicinal product XALATAN 0,005% Colirio en solución PFIZER, S.A has been authorized for the Spainish market on 23/12/1997 under the Marketing authorisation number: 61.756. The SmPC of the originator is also used for Latanoprost Malcosa. Essential Similarity: Eye drops solutions of the Reference products from the Korean and the Dutch market and the Latanoprost Malcosa have been compared with respect to the physicochemical parameters. Samples tested were as follows: Product Strength Country Lot No / Expiry Xalatan® Eye drops solution Korea ND0115 / 03/2009 0.005% Xalatan® Eye drops solution Holland NH0379 / 08/2009 0.005% Latanoprost Malcosa Eye drops solution 7001/ 02/2007 0.005% The results obtained for the assay of Latanoprost in the three formulations under comparison were well within the ±5% limit of the labeled claim. In addition, comparisons of the impurity profile that Xalatan has a relative high percentage of 5,6 trans-Latanoprost but more or less the same profile on the rest of the impurities. Conclusion The comparison of all the above described tests adequately supports the pharmaceutical equivalence of the Latanoprost Malcosa 0.005% Eye drops solution and Xalatan 0.005% Eye drops solution (composition of Latanoprost Malcosa - see confidential part). The applicant summaried the grounds and evidence used for demonstrating that the constituents of Latanoprost Malcosa have a well- established use with an acceptable level of safety and efficacy. Risk management plan: A qualified person responsible for pharmacovigilance activities (QPRP) has been appointed by the applicant to ensure permanent and continous availability for pharmacovigilance activities. A system is in place to ensure the surveillance of Latanoprost Malcosa worldwide. Indication and posology: The proposed indication and posology is in line with the SmPC of the originator. Paediatric indication: A paediatric development could not be recommended at the moment, because the originator has also no paediatric indication. 5/30 a.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. The Qualified Person of., the manufacturer located in the EEA and responsible for batch release, declares that the active substance manufacturer operates in compliance with the detailed guidelines on good manufacturing practice for starting materials. The drug product is manufactured as a sterile ophthalmic solution. The manufacture of the formulation and primary packaging takes place at A copy of the GMP certificate has been provided. Additionally a copy of the GMP certificate issued by the competent Polish Inspection Service, dated 12.05.2008, has been provided. The Main Pharmaceutical Inspector states that the manufacturing conditions for Latanoprost 0.005% eye drops at the manufacturing site , comply with the requirements of Good Manufacturing Practice. The RMS has accepted this copy as certification that acceptable standards of GMP are in place at this site outside the Community. Secondary packaging takes place at Batch release is performed by The RMS has accepted copies of the current manufacturer authorisation and the GMP certificate issued by inspection services of the competent authority of
Load more

Recommended publications
  • Drugs for Glaucoma
    Australian Prescriber Vol. 25 No. 6 2002 Drugs for glaucoma Ivan Goldberg, Eye Associates and Glaucoma Service, Sydney Eye Hospital and the Save Sight Institute, University of Sydney, Sydney SYNOPSIS is not uncommon and the pressure slowly rises. Withdrawing Older drugs for glaucoma reduce intra-ocular pressure, the drug for a few months often re-establishes its efficacy. but often have unpleasant adverse effects. They still The main problem with timolol or levobunolol is their potential have a role in therapy, but there are now newer for systemic adverse effects. These are the same as the adverse drugs which overcome some of the problems. The topical effects of oral beta blockers, the most important of which are carbonic anhydrase inhibitors decrease the secretion of bronchoconstriction, bradyarrhythmias, and an increase in aqueous humour, while lipid-receptor agonists increase falls in the elderly. uveoscleral outflow. Alpha agonists use both mechanisms 2 As betaxolol is relatively selective for beta1 receptors it should to reduce intra-ocular pressure. If a patient needs more pose less respiratory risk. Its pharmacokinetic properties than one drug to control their glaucoma, the new drugs (higher plasma binding and larger volume of distribution) also generally have an additive effect when used in combination make it less likely to provoke other systemic effects. regimens. Miotics Index words: beta blockers, carbonic anhydrase inhibitors, Miotics (pilocarpine and carbachol) are rapidly falling out of lipid-receptor agonists. favour. While their ocular hypotensive efficacy is undisputed, (Aust Prescr 2002;25:142–6) and their systemic safety margin wide (abdominal cramping or diarrhoea are rarely reported), their use is declining because Introduction of their local effects and the need to instill them up to four Glaucoma is the second commonest cause of visual disability times daily.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Systematic Review in Drug's Safety and Clinical
    Ana Sofia Martins Penedones SYSTEMATIC REVIEW: METHODOLOGICAL ASPECTS OF ITS ROLE IN DRUG SAFETY ASSESSMENT Tese no âmbito do Doutoramento em Ciências Farmacêuticas, ramo de Farmácia Clínica orientada pelo Professor Doutor Francisco Jorge Batel Marques e apresentada à Faculdade de Farmácia da Universidade de Coimbra. Março de 2020 Faculdade de Farmácia da Universidade de Coimbra Systematic review: methodological aspects of its role in drug safety assessment Ana Sofia Martins Penedones Tese no âmbito do Doutoramento em Ciências Farmacêuticas, ramo de Farmácia Clínica orientada pelo Professor Doutor Francisco Jorge Batel Marques e apresentada à Faculdade de Farmácia da Universidade de Coimbra. Março de 2020 2 All the research work presented in this thesis was performed in strict collaboration of the Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra and the Centre for Health Technology Assessment and Drug Research, Association for Innovation and Biomedical Research on Light and Image, under the supervision of Professor Francisco Jorge Batel Marques. Todos os trabalhos apresentados nesta tese foram realizados em estreita colaboração entre o Laboratório de Sociofarmácia e Saúde Pública da Faculdade de Farmácia da Universidade de Coimbra e o Centro de Avaliação de Tecnologias em Saúde e Investigação do Medicamento da Associação para Investigação Biomédica e Inovação em Luz e Imagem, sob a supervisão do Professor Doutor Francisco Jorge Batel Marques. 3 4 Agradecimentos Ao meu orientador, Professor Doutor Francisco Batel Marques, pela oportunidade em integrar o seu grupo de trabalho no CHAD – Centre for Health Technology Assessment and Drug Research na AIBILI – Innovation and Biomedical Research on Light and Image.
    [Show full text]
  • Central Nervous System 5 Objectives
    B978-0-7234-3630-0.00005-4, 00005 Central nervous system 5 Objectives After reading this chapter, you will: ● Understand the functions of the central nervous system and the diseases that can occur ● Know the drug classes used to treat these conditions, their mechanisms of action and adverse effects. Parkinson’s disease is progressive, with continued BASIC CONCEPTS loss of dopaminergic neurons in the substantia nigra correlating with worsening of clinical symptoms. The The central nervous system consists of the brain and the possibility of a neurotoxic cause has been strengthe- spinal cord, which are continuous with one another. ned by the finding that 1-methyl-4-phenyl-1,2,3, The brain is composed of the cerebrum (which consists 6-tetrahydropyridine (MPTP), a chemical contaminant of the frontal, temporal, parietal and occipital lobes), of heroin, causes irreversible damage to the nigrostriatal the diencephalon (which includes the thalamus and dopaminergic pathway. Thus, this damage can lead hypothalamus), the brainstem (which consists of the mid- to the development of symptoms similar to those of brain, pons and medulla oblongata) and the cerebellum. idiopathic Parkinson’s disease. Drugs that block The brain functions to interpret sensory information dopamine receptors can also induce parkinsonism. obtained about the internal and external environments Neuroleptic drugs (p. 000) used in the treatment of TS1 and send messages to effector organs in response to a schizophrenia can produce parkinsonian symptoms as situation. Different parts of the brain are associated an adverse effect. Rare causes of parkinsonism are cere- with specific functions (Fig. 5.1). However, the brain is a bral ischaemia (progressive atherosclerosis or stroke), complex organ and is not yet completely understood.
    [Show full text]
  • Drug Delivery System Utilizing Thermosetting Gels
    Europaisches Patentamt European Patent Office 5) Publication number: 3 126 684 Bl Dffice europeen des brevets © EUROPEAN PATENT SPECIFICATION S Date of publication of patent specification: 28.08.91 (£) Int. CI.5: A61 K 47/00, A61K9/06 © Application number: 84400982.9 g) Date of filing: 15.05.84 © Drug delivery system utilizing thermosetting gels. (is) Priority: 16.05.83 US 495238 @ Proprietor: MERCK & CO. INC. 16.05.83 US 495239 126, East Lincoln Avenue P.O. Box 2000 16.05.83 US 495240 Rahway New Jersey 07065-0900(US) 16.05.83 US 495321 @ Inventor: Haslam, John L. @ Date of publication of application: RFD 2, Box 259-B 28.11.84 Bulletin 84/48 Lawrence Kansas 66044(US) Inventor: Higuchi, Takeru © Publication of the grant of the patent: 2811 Schwarz Road 28.08.91 Bulletin 91/35 Lawrence, Kansas 66044(US) Inventor: Mlodozeniec, Arthur R. @ Designated Contracting States: 1704 St. Andrews Drive AT BE CH DE FR GB IT LI LU NL SE Lawrence Kansas 66044(US) @ References cited: AU-A- 482 821 0 Representative: Ahner, Francis et al CA-A- 1 072 413 CABINET REGIMBEAU, 26, avenue Kleber FR-A- 1 598 998 F-75116 Paris(FR) N.F.ESTRIN et al.: "CTFA COSMETIC INGRE- DIENT DICTIONARY", Third Edition, The Cos- metic, Toiletry and Fragrance Association, Inc., Washington, D.C., US; CD 00 CO CO O Note: Within nine months from the publication of the mention of the grant of the European patent, any person - may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • United States Patent (19) 11) Patent Number: 4,861,760 Mazuel Et Al
    United States Patent (19) 11) Patent Number: 4,861,760 Mazuel et al. (45) Date of Patent: Aug. 29, 1989 4,517,216 5/1985 Shim ..................................... 536/1.1 (54) OPHTHALMOLOGICAL COMPOSITION OF 4,563,366 l/1986 Baird et al. .. ... 426/573 THE TYPE WHICH UNDERGOES 4,638,059 1/1987 Sutherland ....... ... 536/123 LIQUID-GEL PHASE TRANSITION 4,661,475 4/1987 Bayerlein et al...................... 514/54 75 Inventors: Claude Mazuel; Marie-Claire 4,717,713 1/1988 Zatz et al. ............................. 514/54 Friteyre, both of Riom, France 4,746,528 5/1988 Prest et al. ........................... 536/1. 73) Assignee: Merck & Co., Inc., Rahway, N.J. FOREIGN PATENT DOCUMENTS 1072413 2/1980 Canada. (21) Appl. No.: 911,606 134649 3/1985 European Pat. Off. (22 Filed: Sep. 25, 1986 0142426 5/1985 European Pat. Off............. 514/914 30 Foreign Application Priority Data 1312244 6/1962 France . Oct. 3, 1985 (FR) France ................................ 85 14689 OTHER PUBLICATIONS 51) Int. Cl." .................... A61K 31/715; A61K 31/70 Jansson et al.; Carbohydrate Research vol. 124:135-139, 52 U.S.C. ...................................... 514/54; 514/912; (1983). 514/913; 514/915; 514/944; 536/1.1; 536/114; Crescenzi et al.; Carbohydrate Research, vol. 536/123 149:425-432, (1986). 58 Field of Search ................. 514/54,944, 912, 913, Primary Examiner-Ronald W. Griffin 514/915,954; 536/123, 114, 1.1 Assistant Examiner-Nancy S. Carson (56) References Cited Attorney, Agent, or Firm-William H. Nicholson; Joseph F. DiPrima U.S. PATENT DOCUMENTS 2,441,729 5/1948 Steiner ............ ... 514/944 57 ABSTRACT 2,935,447 5/1960 Miller et al.
    [Show full text]
  • Reseptregisteret 2011-2015 / Norwegian Prescription
    legemiddel- statistikk 2016:2 Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 legemiddel- statistikk 2016:2 Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 Christian Berg Hege Salvesen Blix Olaug Fenne Kari Jansdotter Husabø Randi Selmer Sissel Torheim Kari Furu Rapport 2016:2 Nasjonalt folkehelseinstitutt / The Norwegian Institute of Public Health Tittel/Title: Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 Redaktør/Editor: Christian Berg Forfattere/Authors: Christian Berg Hege Salvesen Blix Olaug Fenne Kari Jansdotter Husabø Randi Selmer Sissel Torheim Kari Furu Publisert av / Published by: Folkehelseinstituttet Postboks 4404 Nydalen NO-0403 Norway Tel: + 47 21 07 70 00 E-mail: [email protected] www.fhi.no Design/Layout Houston911 Acknowledgement: Julie D.W. Johansen (English version) Forsideillustrasjon / Front page illustration: Dreamstime Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no Only available as PDF from www.fhi.no ISSN: 1890-9647 ISBN: 978-82-8082-714-2 Tidligere utgave / Previous edition: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs 2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010 2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011 / The Norwegian Prescription Database 2007–2011 2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008–2012 / The Norwegian Prescription Database 2008–2012 2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009–2013. / The Norwegian Prescription Database 2009–2013 2015: Legemiddelstatistikk 2015:2: Reseptregisteret 2010–2014.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • Supplementary Materials
    1 Table 1. Validated drug-target interactions for Enzyme data. Target Annotation Drugs Drug Annotation Database Annotation hsa1543 cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) D00139' Methoxsalen (JP16/USP); Oxsoralen (TN) DrugBank hsa1571 cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) D00542 Halothane (JP16/USP/INN);Fluothane (TN) DrugBank hsa1200 tripeptidyl peptidase I (EC:3.4.14.9) D00160 Epsilon-Aminocaproic acid (JAN);Aminocaproic acid (USP/INN);Amicar (TN) DrugBank hsa1559 cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) D00437 Nifedipine (JP16/USP/INN); Adalat (TN); Afeditab CR (TN); Procardia (TN) DrugBank hsa5478 peptidylprolyl isomerase A (cyclophilin A) (EC:5.2.1.8) D00184 Ciclosporin (JP16); Cyclosporine (USP); Gengraf (TN); Neoral (TN);Restasis (TN); Sandimmune (TN) DrugBank hsa5150 phosphodiesterase 7A (EC:3.1.4.53) D00528 Anhydrous caffeine (JP16); Caffeine (USP); Anhydrous caffeine (TN); Respia (TN) KEGG hsa5150 phosphodiesterase 7A (EC:3.1.4.53) D00691 Diprophylline (JAN/INN); Dyphylline (USP); Lufyllin (TN) DrugBank hsa4128 monoamine oxidase A (EC:1.4.3.4) D05458 Phentermine (USAN/INN) DrugBank hsa57016 aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) D02323 Tolrestat (USAN/INN); Alredase (TN) DrugBank hsa1585 CYP11B2, ALDOS, CPN2, CYP11B, CYP11BL, CYPXIB2, P-450C18, P450C18, P450aldo D00410 Metyrapone (JP16/USP/INN); Metopirone (TN) DrugBank hsa50940 phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) D00528 Anhydrous caffeine (JP16); Caffeine (USP); Anhydrous caffeine (TN);Respia (TN) KEGG hsa4129 monoamine oxidase B (EC:1.4.3.4) D00947 Linezolid (JAN/USAN/INN); Zyvox (TN) DrugBank Table 2.
    [Show full text]
  • References Case Report
    chromosome be active in a sufficient proportion of cells 9. Schwartz M, Yang HM, Niebuhr E, Rosenberg T, Page DC. in a tissue in which the gene is expressed then a female Regional localisation of polymorphic DNA loci on the proximal long arm of the X chromosome using deletions may manifest the disease in that tissue. If cells of only associated with choroideremia. Hum Genet 1988;78:156-60. parts of that tissue are affected then a mosaic pattern may 10. Van Bokhoven H, Van den Hurk JA, Bogerd L, Philippe C. be demonstrated. The X-inactivation ratio determines the Gilgenkrantz S, DeJong P, et al. Cloning and characterisation degree to which the tissue is affected and in our patient of the human choroideremia gene. Hum Mol Genet 1994;3:1041-6. could explain the laterality of involvement. 11. Lyon MF. Gene action in the X-chromosome of the mouse It might be argued that these changes are due to other (Mus musculus). Nature 1961;190:372. causes. Age-related macular degeneration is a possibility; 12. Jay B. X-linked retinal disorders and the Lyon hypothesis. however, the relatively early age of onset, paucity of Trans Ophthalmol Soc UK 1985;104:836-44. drusen and marked asymmetry of the macular findings 13. Flannery JG, Bird AC, Farber DB, Weleber RG, Bok D. A histopathologic study of a choroideremia carrier. Invest are somewhat atypical. Serpiginous choroiditis Ophthalmol Vis Sci 1990;31:229-36. commencing at and involving solely the macular region 14. Mansour AM, Jampol LM, Packo KH, Hrisomalos NF. has been described.l4,ls Involvement is bilateral, Macular serpiginous choroiditis.
    [Show full text]
  • Pharmacology for Optometry
    FACULTY OF MEDICINE SCHOOL OF MEDICAL SCIENCES DEPARTMENT OF PHARMACOLOGY PHAR3306 PHARMACOLOGY FOR OPTOMETRY COURSE OUTLINE Session 2, 2010 Page | 1 CONTENTS PAGE I. Course Information ……………………………………………………………………… 2 Units of credit (UOC) …………………………………………………………………… 2 Prerequisites……………………………………………………………………………… 2 Objectives of the course ………………………………………………………………… 2 Course co-ordinators …………………………………………………………………… 2 Lecturers in this course ………………………………………………………………… 2 Course structure and teaching strategies ………………………………………………… 3 Approach to learning and teaching ……………………………………………………… 3 Student learning outcomes ………………………………………………………………… 3 Assessment procedures …………………………………………………………………… 4 Textbooks …………………………………………………………………………………… 5 Course evaluation and development …………………………………………………… 5 General information ………………………………………………………………………… 5 Official communication by email ………………………………………………………… 6 Attendance requirements ………………………………………………………………… 6 Behaviour and Safety in practical classes ……………………………………………… 6 Noticeboards ………………………………………………………………………………… 6 WWW teaching resources ………………………………………………………………… 7 Handwriting ………………………………………………………………………………… 7 Student right and responsibilities ………………………………………………………… 7 Special consideration ……………………………………………………………………… 7 Missed assessment items ……..…………………………………………………………… 7 Missed practical classes …………………………………………………………………… 8 Medical certificates ………………………………………………………………………… 8 Repeating students ………………………………………………………………………… 8 Student support services …………………………………………………………………… 8 Appeal procedures …………………………………………………………………………
    [Show full text]